RecruitMe Clinical Trial

A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physicians Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent
Study of Rigosertib in Patients with Myelodysplastic Syndrome (MDS)
Sponsor:Onconova Therapeutics Inc.
Enrolling:Male and Female Patients
Age Range:Between 18 and 79 years old
IRB Number:AAAP9823
U.S. Government ID:NCT02562443
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to determine how well a drug called rigosertib works on people with MDS and to study the safety of rigosertib when it is given to people with MDS. Rigosertib is currently being tested in other clinical research studies.

This study is closed
Investigator
Mark Heaney, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162